Federated Hermes’s G1 Therapeutics GTHX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-4,522
Closed -$10.3K – 2201
2024
Q2
$10.3K Buy
4,522
+2,490
+123% +$9.5K ﹤0.01% 1773
2024
Q1
$8.78K Buy
2,032
+613
+43% +$2.14K ﹤0.01% 1792
2023
Q4
$4.33K Sell
1,419
-1,855
-57% -$3.49K ﹤0.01% 1867
2023
Q3
$4.72K Buy
+3,274
New +$6.34K ﹤0.01% 1890
2022
Q3
– Sell
-179,472
Closed -$887K – 2269
2022
Q2
$887K Buy
179,472
+139,872
+353% +$775K ﹤0.01% 1188
2022
Q1
$301K Buy
39,600
+13,084
+49% +$124K ﹤0.01% 1540
2021
Q4
$271K Sell
26,516
-33,617
-56% -$428K ﹤0.01% 1594
2021
Q3
$807K Buy
+60,133
New +$980K ﹤0.01% 1363
2021
Q1
– Sell
-25,188
Closed -$453K – 2365
2020
Q4
$453K Sell
25,188
-398,023
-94% -$5.95M ﹤0.01% 1536
2020
Q3
$4.89M Buy
423,211
+234,045
+124% +$3.86M 0.01% 733
2020
Q2
$4.59M Buy
189,166
+141,296
+295% +$2.34M 0.01% 738
2020
Q1
$528K Buy
+47,870
New +$894K ﹤0.01% 1360
2019
Q4
– Sell
-20,015
Closed -$456K – 2323
2019
Q3
$456K Buy
20,015
+18,183
+993% +$573K ﹤0.01% 1466
2019
Q2
$56K Sell
1,832
-207
-10% -$4.36K ﹤0.01% 1661
2019
Q1
$34K Buy
2,039
+1,011
+98% +$19.2K ﹤0.01% 1697
2018
Q4
$20K Sell
1,028
-74,048
-99% -$2.77M ﹤0.01% 1775
2018
Q3
$3.93M Buy
75,076
+21,217
+39% +$1.16M 0.01% 879
2018
Q2
$2.34M Buy
+53,859
New +$2.31M 0.01% 948

Federated Hermes's GTHX Position: Q3 2024 in Review

Federated Hermes sold out of G1 Therapeutics (GTHX) in Q3 2024, closing a stake of 4,522 shares — an estimated $10.3K sold.

Federated Hermes first reported a position in GTHX in Q2 2018 and held it in 18 quarters. The position peaked at $4.89M in Q3 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.

  • Federated Hermes reported no remaining G1 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Federated Hermes sold 4,522 G1 Therapeutics shares in Q3 2024, an estimated $10.3K.
  • Federated Hermes first reported a position in G1 Therapeutics in Q2 2018 and held it in 18 quarters.
  • Federated Hermes's G1 Therapeutics position peaked at $4.89M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held G1 Therapeutics as of Q3 2024.

Based on Federated Hermes's 13F filing for Q3 2024, filed 13 Nov 2024.